Home Companies Orphazyme A/S (ORPH) Stock Plummeting After Failure of ORAIALS-01 Trial Announced

Orphazyme A/S (ORPH) Stock Plummeting After Failure of ORAIALS-01 Trial Announced

Orphazyme A/S (ORPH) stock prices plummeted by 27.77%  after the market opened on May 7th, 2021, bringing the price per share tumbling down to USD$6.12 after the commencing of the trading day.

ORAIALS-01 Ends in Failure

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

The company announced on May 7th, 2021 that the ORAIALS-01 pivotal trial of arimoclomol in amyotrophic lateral sclerosis (ALS) did not meet its primary and secondary endpoints. While the trial did not report any significant safety signals, topline data will be disclosed in an ENCALS virtual meeting from May 12th to 14th 2021. Complete data from the study is scheduled to be published later in 2021.

Making the Most of the Situation

The disheartening conclusion of arimoclomol failing to benefit the demographic gripped by ALS was not in vain, however. As one of the longest-running clinical studies in its category, the 18 months of evaluation have yielded data that the company hopes will meaningfully contribute to the scientific dialogue on and around ALS. ORPH will also apply the invaluable insights gained from its previous studies to further develop its pipeline as the company continues to facilitate the actualization of the full potential of the heat shock protein response.

Details of the Trial

The third phase of the trial was randomized and placebo-controlled, with 245 patients spread out across 29 sites over 12 countries in North America and Europe. The administration of either arimoclomol or a placebo for 76 weeks was determined randomly, with one patient being given a placebo for every two patients that got the drug.

Details of Endpoints

The primary endpoint was to establish the effectiveness of consistent treatment with the drug in participants with ALS as assessed by the combined assessment of function and survival (CAFS), with the placebo control group serving as a baseline from which results were hoped to vary significantly. This endpoint served to emphasize the net treatment effect based on survival and changes in the ALS Functional Rating Scale-Revised score. Secondary endpoints included these bases, as well as slow vital capacity (SVC).

Future Outlook for 2021

The news of the ORAIALS-01 pivotal trial’s failure to meet endpoints has spelled apparent doom for ORPH stock prices. As the prices continue to spiral, the company must prove prospects of profitability elsewhere in is pipeline and product portfolio.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Tyme Technologies, Inc. (TYME) Stock Trends downwards Following Strong Q4 2021 Financials and Progress in OASIS Trial

Tyme Technologies, Inc. (TYME) stock prices was down by -6.92% shortly after market trading commenced on June 11th, 2021, bringing the price per share...

Prophase Labs Inc. (PRPH) stock surged during pre-market trading session. Let’s figure out why?

Prophase Labs Inc. (NASDAQ: PRPH) stock soared by 5.87% at last close as well as the PRPH stock price has been observed rising by...

Why Surgalign Holdings, Inc. (SRGA) stock is gloomy today?

Surgalign Holdings, Inc. (SRGA) stock announced the $50 million registered direct offering priced at the market under Nasdaq rules today on June 10, 2021,...

Exela Technologies Inc. (XELA) stock soars during pre-market. Here’s what you should know?

Exela Technologies Inc. (NASDAQ: XELA) stock gained by 8.28% at last close while the XELA stock price rises in the pre-market as well, by...

Atossa Therapeutics, Inc. (ATOS) stock gains during pre-market trading. Here’s to know why?

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock declined by 27.51% at the last close while the ATOS stock price rises further by 9.09% in the...

Tyme Technologies, Inc. (TYME) Stock Trends downwards Following Strong Q4 2021 Financials and Progress in OASIS Trial

Tyme Technologies, Inc. (TYME) stock prices was down by -6.92% shortly after market trading commenced on June 11th, 2021, bringing the price per share...

Magnachip Semiconductor Corporation (MX) stock is Popping High today: Why is it so?

Shares of the Magnachip Semiconductor Corporation (MX) stock were popping high after the announcement of its receival of unsolicited buyout bid from Cornucopia Investment...

Why is Autolus Therapeutics plc (AUTL) stock rising today?

Shares of  Autolus Therapeutics plc (AUTL) stock were rising today on June 11, 2021, following the release of the presentation data related to obe-cel...

Related News

Lumentum Holdings Inc. (LITE) Stock Drops Despite Promising Fiscal Q3 2021 Financial Reports

Lumentum Holdings Inc. (LITE) stock prices were down by a significant 16.42% shortly after market trading commenced, bringing the price per share down to...

Lucira Health Inc. (NASDAQ:LHDX) stock rallied today in the current trading session; here’s why

In the current trading session at last check, Lucira Health Inc. (LHDX) shares had surged by 15.32% to the price of $5.87. LHDX's stock...

Comstock Mining Inc. (NASDAQ:LODE) stock plunged in the current trading session; here’s why

In the current trading session at the last check, Comstock Mining Inc. (LODE) stock had plunged -3.25% to trade at $3.21. LODE stock previously...

Greenpro Capital Corp. (GRNQ) Stock Price Is Rising Immensely, Here is What You Need to Know

Greenpro Capital Corp. (NASDAQ: GRNQ) a leading company primarily focused on the provision of cloud system resolution, financial consulting services, and corporate accounting services,...

Tilray Inc. (NASDAQ: TLRY) stock rises during current market trading. What is driving it high?

Tilray Inc. (NASDAQ: TLRY) stock gains by 17.17% in the current market trading. Tilray is a world leader in cannabis and cannabinoid research, cultivation,...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam